T1	CHEM 1 16	Dexmedetomidina
#1	AnnotatorNotes T1	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T2	CHEM 24 33	lidocaína
#2	AnnotatorNotes T2	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T3	PROC 51 77	control de dolor irruptivo
T4	DISO 114 135	canal lumbar estrecho
#3	AnnotatorNotes T4	C0158288; Spinal stenosis of lumbar region; Disease or Syndrome
T5	ANAT 241 253	canal lumbar
#4	AnnotatorNotes T5	C1281715; Entire lumbar spinal canal; Body Space or Junction + C0223491; Structure of lumbar spinal canal; Body Space or Junction
T6	CHEM 267 282	dexmedetomidina
#5	AnnotatorNotes T6	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T7	CHEM 288 298	analgésico
#6	AnnotatorNotes T7	C0002771; Analgesics; Organic Chemical · Pharmacologic Substance · Hazardous or Poisonous Substance
T8	CHEM 381 416	receptores de aspartato y glutamato
T9	CHEM 333 344	sustancia P
#7	AnnotatorNotes T9	C0038585; Substance P; Amino Acid, Peptide, or Protein · Biologically Active Substance
T10	DISO 752 773	canal lumbar estrecho
#8	AnnotatorNotes T10	C0158288; Spinal stenosis of lumbar region; Disease or Syndrome
T11	PROC 1012 1019	tratado
#9	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	PROC 1066 1073	tratado
#10	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	CHEM 436 445	lidocaína
#11	AnnotatorNotes T13	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T14	PROC 454 462	previene
#12	AnnotatorNotes T14	C0199176; Prophylactic treatment; Therapeutic or Preventive Procedure
T15	CHEM 544 552	receptor
#13	AnnotatorNotes T15	C0597357; receptor; Amino Acid, Peptide, or Protein · Receptor
T16	CHEM 578 594	canales de sodio
#14	AnnotatorNotes T16	C0037492; Sodium Channel; Amino Acid, Peptide, or Protein · Biologically Active Substance
T17	PROC 608 627	Evaluar la eficacia
#15	AnnotatorNotes T17	C1707887; Efficacy Study; Research Activity
T18	PROC 1644 1652	tratados
#16	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	CHEM 645 660	dexmedetomidina
#17	AnnotatorNotes T19	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T20	CHEM 668 677	lidocaína
#18	AnnotatorNotes T20	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T21	PROC 681 701	perfusión endovenosa
#19	AnnotatorNotes T21	C0021440; Intravenous infusion procedures; Therapeutic or Preventive Procedure
T22	PROC 707 738	tratamiento del dolor irruptivo
T23	PROC 1710 1718	tratados
#20	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	PROC 1134 1193	medición de la intensidad del dolor y el estado de sedación
T25	PROC 936 947	diagnóstico
#21	AnnotatorNotes T25	C0011900; Diagnosis; Diagnostic Procedure
T26	DISO 980 1001	canal lumbar estrecho
#22	AnnotatorNotes T26	C0158288; Spinal stenosis of lumbar region; Disease or Syndrome
T27	CHEM 1024 1039	dexmedetomidina
#23	AnnotatorNotes T27	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T28	CHEM 1078 1087	lidocaína
#24	AnnotatorNotes T28	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T29	PROC 1101 1121	perfusión endovenosa
#25	AnnotatorNotes T29	C0021440; Intravenous infusion procedures; Therapeutic or Preventive Procedure
T30	PROC 1214 1225	tratamiento
#26	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	PROC 1279 1305	se evaluó la funcionalidad
T32	DISO 1346 1358	discapacidad
#27	AnnotatorNotes T32	C0231170; Disability; Finding
T33	PROC 1400 1411	tratamiento
#28	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	PROC 1460 1472	tratamientos
#29	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	CHEM 1657 1672	dexmedetomidina
#30	AnnotatorNotes T35	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T36	PROC 1674 1677	EVA
#31	AnnotatorNotes T36	C0042815; Visual Analog Pain Scale; Diagnostic Procedure | C2959685; Assessment using visual analog scale; Health Care Activity
T37	CHEM 1723 1732	lidocaína
#32	AnnotatorNotes T37	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T38	PROC 1734 1737	EVA
#33	AnnotatorNotes T38	C0042815; Visual Analog Pain Scale; Diagnostic Procedure | C2959685; Assessment using visual analog scale; Health Care Activity
T39	PROC 1790 1799	perfusión
#34	AnnotatorNotes T39	C0031001; Perfusion (procedure); Therapeutic or Preventive Procedure
T40	CHEM 1820 1835	dexmedetomidina
#35	AnnotatorNotes T40	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T41	CHEM 1878 1887	lidocaína
#36	AnnotatorNotes T41	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T42	PROC 1907 1919	tratamientos
#37	AnnotatorNotes T42	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T43	PROC 2030 2042	tratamientos
#38	AnnotatorNotes T43	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T44	CHEM 2136 2151	dexmedetomidina
#39	AnnotatorNotes T44	C0113293; dexmedetomidine; Organic Chemical · Pharmacologic Substance
T45	CHEM 2157 2166	lidocaína
#40	AnnotatorNotes T45	C0023660; lidocaine; Organic Chemical · Pharmacologic Substance
T46	PROC 2197 2228	tratamiento del dolor irruptivo
T47	PROC 2293 2302	perfusión
#41	AnnotatorNotes T47	C0031001; Perfusion (procedure); Therapeutic or Preventive Procedure
T48	DISO 2350 2381	eventos adversos medicamentosos
#42	AnnotatorNotes T48	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T49	DISO 62 77	dolor irruptivo
#43	AnnotatorNotes T49	C1135120; Breakthrough Pain; Sign or Symptom
T50	ANAT 114 126	canal lumbar
#44	AnnotatorNotes T50	C1281715; Entire lumbar spinal canal; Body Space or Junction + C0223491; Structure of lumbar spinal canal; Body Space or Junction
T51	DISO 155 160	dolor
#45	AnnotatorNotes T51	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T52	DISO 212 227	dolor irruptivo
#46	AnnotatorNotes T52	C1135120; Breakthrough Pain; Sign or Symptom
T53	DISO 241 262	canal lumbar estrecho
#47	AnnotatorNotes T53	C0158288; Spinal stenosis of lumbar region; Disease or Syndrome
T54	DISO 475 480	dolor
#48	AnnotatorNotes T54	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T55	DISO 723 738	dolor irruptivo
#49	AnnotatorNotes T55	C1135120; Breakthrough Pain; Sign or Symptom
T56	ANAT 752 764	canal lumbar
#50	AnnotatorNotes T56	C1281715; Entire lumbar spinal canal; Body Space or Junction + C0223491; Structure of lumbar spinal canal; Body Space or Junction
T57	PROC 797 850	Ensayo clínico controlado, aleatorizado, triple ciego
#51	AnnotatorNotes T57	C1883398; Triple Blind Study; Research Activity + C0206035; Controlled Clinical Trials, Randomized; Research Activity
T58	DISO 880 885	dolor
#52	AnnotatorNotes T58	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T59	DISO 951 966	dolor irruptivo
#53	AnnotatorNotes T59	C1135120; Breakthrough Pain; Sign or Symptom
T60	ANAT 980 992	canal lumbar
#54	AnnotatorNotes T60	C1281715; Entire lumbar spinal canal; Body Space or Junction + C0223491; Structure of lumbar spinal canal; Body Space or Junction
T61	DISO 1164 1169	dolor
#55	AnnotatorNotes T61	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T62	DISO 1600 1605	dolor
#56	AnnotatorNotes T62	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T63	CHEM 1807 1815	fármacos
#57	AnnotatorNotes T63	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T64	PROC 1850 1858	sedación
#58	AnnotatorNotes T64	C0344106; Sedation procedure; Therapeutic or Preventive Procedure
T65	DISO 2213 2228	dolor irruptivo
#59	AnnotatorNotes T65	C1135120; Breakthrough Pain; Sign or Symptom
T66	Route 34 44	endovenosa
#60	AnnotatorNotes T66	C1522726; Intravenous Route of Drug Administration; Functional Concept
T67	LIVB 100 109	pacientes
#61	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T69	PHYS 355 366	nociceptiva
#62	AnnotatorNotes T69	C0234194; Nociception; Organ or Tissue Function
T72	Route 691 701	endovenosa
#63	AnnotatorNotes T72	C1522726; Intravenous Route of Drug Administration; Functional Concept
T73	LIVB 922 931	pacientes
#64	AnnotatorNotes T73	C0030705; Patients; Patient or Disabled Group
T74	Dose 1041 1051	0,3 mcg/kg
T75	Dose 1089 1096	2 mg/kg
T77	Route 1111 1121	endovenosa
#65	AnnotatorNotes T77	C1522726; Intravenous Route of Drug Administration; Functional Concept
T78	Duration 1245 1269	los 30, 60 y 120 minutos
T79	LIVB 1313 1322	pacientes
#66	AnnotatorNotes T79	C0030705; Patients; Patient or Disabled Group
T80	Duration 1381 1395	los siete días
T83	Duration 1608 1623	los 120 minutos
T84	LIVB 1634 1643	pacientes
#67	AnnotatorNotes T84	C0030705; Patients; Patient or Disabled Group
T86	LIVB 1958 1967	pacientes
#68	AnnotatorNotes T86	C0030705; Patients; Patient or Disabled Group
T90	Duration 2254 2277	los primeros 30 minutos
T92	Duration 2309 2331	las siguientes 2 horas
T93	Neg_cue 2333 2335	No
T68	PHYS 512 527	neuroconducción
#69	AnnotatorNotes T68	C0027788; Nerve conduction function; Organ or Tissue Function
T70	PROC 2101 2115	signos vitales
#70	AnnotatorNotes T70	C2963216; Vital signs measurements; Health care activity
T71	PROC 1483 1497	signos vitales
#71	AnnotatorNotes T71	C2963216; Vital signs measurements; Health care activity
A1	Assertion T48 Negated
R1	Negation Arg1:T93 Arg2:T48	
T76	Neg_cue 1513 1515	No
T81	CONC 1521 1531	diferencia
A2	Assertion T81 Negated
#72	AnnotatorNotes T81	C1705241; Delta (difference); Quantitative Concept
R2	Negation Arg1:T76 Arg2:T81	
T82	Observation 2072 2090	efectos depresores
A3	Assertion T82 Negated
T85	Neg_cue 2055 2057	no
R3	Negation Arg1:T85 Arg2:T82	
T87	Neg_cue 1968 1971	sin
T88	CONC 1978 1988	diferencia
A4	Assertion T88 Negated
#73	AnnotatorNotes T88	C1705241; Delta (difference); Quantitative Concept
R4	Negation Arg1:T87 Arg2:T88	
R5	Has_Route_or_Mode Arg1:T2 Arg2:T66	
R6	Used_for Arg1:T2 Arg2:T3	
R7	Used_for Arg1:T1 Arg2:T3	
R9	Experiences Arg1:T67 Arg2:T4	
R10	Location_of Arg1:T50 Arg2:T4	
R11	Experiences Arg1:T67 Arg2:T2	
R12	Experiences Arg1:T67 Arg2:T3	
R13	Experiences Arg1:T67 Arg2:T1	
T89	Observation 177 195	ausentismo laboral
#74	AnnotatorNotes T89	C0557442; On sick leave from work; Finding | C2108469; job absence; Finding
R14	Causes Arg1:T51 Arg2:T89	
R15	Causes Arg1:T52 Arg2:T89	
R16	Causes Arg1:T53 Arg2:T52	
R17	Location_of Arg1:T5 Arg2:T53	
R18	Used_for Arg1:T13 Arg2:T14	
T91	Observation 465 471	alivia
#75	AnnotatorNotes T91	C0564405; Feeling relief; Finding 
R19	Causes Arg1:T13 Arg2:T91	
R20	Before Arg1:T54 Arg2:T91	
R21	Has_Route_or_Mode Arg1:T20 Arg2:T72	
R22	Used_for Arg1:T20 Arg2:T22	
R24	Causes Arg1:T10 Arg2:T55	
R25	Location_of Arg1:T56 Arg2:T10	
R26	Experiences Arg1:T73 Arg2:T59	
R27	Location_of Arg1:T60 Arg2:T26	
R28	Causes Arg1:T26 Arg2:T59	
R29	Experiences Arg1:T73 Arg2:T26	
R30	Experiences Arg1:T73 Arg2:T58	
R31	Experiences Arg1:T73 Arg2:T11	
R32	Has_Dose_or_Strength Arg1:T27 Arg2:T74	
R33	Used_for Arg1:T27 Arg2:T11	
R34	Used_for Arg1:T28 Arg2:T12	
R35	Has_Dose_or_Strength Arg1:T28 Arg2:T75	
R37	Has_Route_or_Mode Arg1:T28 Arg2:T77	
R38	Experiences Arg1:T73 Arg2:T12	
R39	Has_Route_or_Mode Arg1:T1 Arg2:T66	
R40	Has_Route_or_Mode Arg1:T19 Arg2:T72	
R41	Used_for Arg1:T19 Arg2:T22	
R43	Has_Route_or_Mode Arg1:T27 Arg2:T77	
R46	Before Arg1:T24 Arg2:T30	
R47	After Arg1:T24 Arg2:T78	
R48	Experiences Arg1:T79 Arg2:T31	
T94	CONC 1336 1370	índice de discapacidad de Oswestry
#76	AnnotatorNotes T94	C0451360; Oswestry disability index; Intellectual Product
R49	Used_for Arg1:T94 Arg2:T31	
R50	Before Arg1:T31 Arg2:T33	
R51	After Arg1:T31 Arg2:T80	
R53	Experiences Arg1:T79 Arg2:T33	
R54	Experiences Arg1:T79 Arg2:T32	
T95	Observation 1446 1452	efecto
#77	AnnotatorNotes T95	C1518681; Outcome of Therapy; Finding (?)
R55	Causes Arg1:T34 Arg2:T95	
T96	Quantifier_or_Qualifier 1532 1562	estadísticamente significativa
A5	Assertion T96 Negated
#78	AnnotatorNotes T96	C0237881; Statistical Significance; Quantitative Concept
R57	Has_Quantifier_or_Qualifier Arg1:T81 Arg2:T96	
T97	Observation 1569 1605	reducción de la intensidad del dolor
#79	AnnotatorNotes T97	C5230944; Sensation of pain reduced; Finding
R58	Before Arg1:T62 Arg2:T97	
R59	Overlap Arg1:T97 Arg2:T83	
R60	Experiences Arg1:T84 Arg2:T97	
R61	Experiences Arg1:T84 Arg2:T18	
R62	Experiences Arg1:T84 Arg2:T62	
R63	Used_for Arg1:T35 Arg2:T18	
R64	Experiences Arg1:T84 Arg2:T36	
R65	Overlap Arg1:T36 Arg2:T83	
R66	Experiences Arg1:T84 Arg2:T23	
R67	Used_for Arg1:T37 Arg2:T23	
R68	Experiences Arg1:T84 Arg2:T38	
R69	Overlap Arg1:T38 Arg2:T83	
R70	Used_for Arg1:T63 Arg2:T64	
R71	Used_for Arg1:T40 Arg2:T64	
R72	Used_for Arg1:T41 Arg2:T64	
R73	Before Arg1:T39 Arg2:T64	
R74	Experiences Arg1:T86 Arg2:T42	
T98	Quantifier_or_Qualifier 1989 2019	estadísticamente significativa
A6	Assertion T98 Negated
#80	AnnotatorNotes T98	C0237881; Statistical Significance; Quantitative Concept
R75	Has_Quantifier_or_Qualifier Arg1:T88 Arg2:T98	
R76	Negation Arg1:T87 Arg2:T98	
R77	Experiences Arg1:T86 Arg2:T82	
R78	Experiences Arg1:T86 Arg2:T43	
R80	Experiences Arg1:T86 Arg2:T70	
R82	Used_for Arg1:T45 Arg2:T46	
R83	Used_for Arg1:T44 Arg2:T46	
T99	CONC 2234 2250	inicio de acción
R84	After Arg1:T99 Arg2:T90	
R85	Before Arg1:T47 Arg2:T99	
R89	Before Arg1:T99 Arg2:T92	
R36	Before Arg1:T47 Arg2:T46	
R44	Negation Arg1:T76 Arg2:T96	
#81	AnnotatorNotes T8	C0052536; aspartic acid receptor; Amino Acid, Peptide, or Protein · Receptor + C0061465; Glutamate Receptor; Amino Acid, Peptide, or Protein · Receptor
R8	Before Arg1:T14 Arg2:T54	
R23	Before Arg1:T42 Arg2:T82	
#82	AnnotatorNotes T99	C2986534; Onset of Action; Temporal Concept
#83	AnnotatorNotes T31	C0278372; Functional assessment; Laboratory Procedure
A7	Experiencer T79 Patient
A8	Experiencer T67 Patient
A9	Experiencer T73 Patient
A10	Experiencer T84 Patient
A11	Experiencer T86 Patient
